Jazz Pharmaceuticals plc (JAZZ) stock
JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 11/3015% below fair value
$215.98+8.15 (+3.92%)
Close on Oct 30, 2026Market cap $14.02BP/E 14.8Yield –
Earnings
Jazz Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Feb 23, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q1 FY2026
$1.07B
+19.0% on a year earlier
non-GAAP adjusted earnings per share, Q1 FY2026
$6.34
$1.68 a year earlier
Latest guidance
Lowered
May 5, 2026 · 11 items
Quarterly results
Revenue and earnings per share from each of Jazz Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 23, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 26, 2026after the close | – | – | – | – | Filing |
| Q2 FY2026ended Jun 30, 2026 | Aug 3, 2026after the close | – | – | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 5, 2026after the close | $1.07B | +19.0% | $4.43 | $6.34 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 24, 2026after the close | $1.20B | +10.1% | $3.21 | $6.64 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 5, 2025after the close | $1.13B | +6.7% | $4.08 | $8.13 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 5, 2025after the close | $1.05B | +2.6% | -$11.74 | -$8.25 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 6, 2025after the close | $898.00M | -0.4% | -$1.52 | $1.68 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 25, 2025after the close | $1.09B | +7.5% | $3.11 | $6.60 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 6, 2024after the close | $1.05B | +8.5% | $3.42 | $6.61 | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 31, 2024after the close | $1.02B | +7.0% | $2.49 | $5.30 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 1, 2024after the close | $901.98M | +1.0% | -$0.23 | $2.68 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 28, 2024after the close | $1.01B | +4.1% | $1.42 | $5.02 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 8, 2023after the close | $972.00M | +3.3% | $2.14 | $4.84 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 9, 2023after the close | $957.00M | +2.6% | $1.52 | $4.51 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 10, 2023after the close | $892.80M | +9.7% | $1.04 | $3.95 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 1, 2023after the close | $972.12M | +8.4% | -$3.82 | -$0.07 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 9, 2022after the close | $940.70M | +12.2% | -$0.31 | $5.17 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 3, 2022after the close | $932.90M | – | $0.55 | $4.30 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 4, 2022after the close | $813.70M | – | $0.03 | $3.73 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 1, 2022after the close | $896.73M | – | -$0.57 | $4.21 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 9, 2021after the close | $838.10M | – | -$0.86 | $4.20 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 3, 2021after the close | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 20, 2021before the open | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 23, 2021after the close | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 2, 2020after the close | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Jazz Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Total Revenues | FY2026 | $4.25B – $4.50B | – | New | May 5, 2026 |
| Total Revenues | FY2026 | $4.25B – $4.50B | – | New | Feb 24, 2026 |
| Gross margin %GAAP | FY2026 | 89% – 90% | – | New | May 5, 2026 |
| Gross margin %non-GAAP | FY2026 | 90% – 91% | – | New | May 5, 2026 |
| Gross margin %GAAP | FY2026 | 89% – 90% | – | New | Feb 24, 2026 |
| Gross margin %non-GAAP | FY2026 | 90% – 91% | – | New | Feb 24, 2026 |
| Effective tax rateGAAP | FY2026 | 0% – 10% | – | New | May 5, 2026 |
| Effective tax ratenon-GAAP | FY2026 | 11.5% – 13.5% | – | New | May 5, 2026 |
| Effective tax rateGAAP | FY2026 | 0% – 10% | – | New | Feb 24, 2026 |
| Effective tax ratenon-GAAP | FY2026 | 11.5% – 13.5% | – | New | Feb 24, 2026 |
| R&D expensesGAAP | FY2026 | $811.00M – $867.00M | – | Lowered | May 5, 2026 |
| R&D expensesnon-GAAP | FY2026 | $725.00M – $775.00M | – | Lowered | May 5, 2026 |
| R&D expensesGAAP | FY2026 | $811.00M – $867.00M | – | Lowered | Feb 24, 2026 |
| R&D expensesnon-GAAP | FY2026 | $725.00M – $775.00M | – | Lowered | Feb 24, 2026 |
| SG&A expensesGAAP | FY2026 | $1.42B – $1.50B | – | New | May 5, 2026 |
| SG&A expensesnon-GAAP | FY2026 | $1.26B – $1.32B | – | New | May 5, 2026 |
| SG&A expensesGAAP | FY2026 | $1.42B – $1.50B | – | New | Feb 24, 2026 |
| SG&A expensesnon-GAAP | FY2026 | $1.26B – $1.32B | – | New | Feb 24, 2026 |
| Weighted-average ordinary shares outstandingGAAP | FY2026 | 66 – 67 | – | New | May 5, 2026 |
| Weighted-average ordinary shares outstandingnon-GAAP | FY2026 | 66 – 67 | – | New | May 5, 2026 |
| Weighted-average ordinary shares outstandingGAAP | FY2026 | 65 – 66 | – | New | Feb 24, 2026 |
| Weighted-average ordinary shares outstandingnon-GAAP | FY2026 | 65 – 66 | – | New | Feb 24, 2026 |
Guidance vs results
The last range Jazz Pharmaceuticals gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | EPS (GAAP) | -$7.10 – -$5.20 | -$5.97Σ4Q | Within range |
| FY2025 | Net income per diluted share | $7.65 – $8.45 | $8.20Σ4Q | Within range |
| FY2025 | Revenue | $4.18B – $4.28B | $4.27BΣ4Q | Within range |
Guidance history
Every forecast Jazz Pharmaceuticals put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| May 5, 2026 | Gross margin % | FY2026 | 89% – 90% | New |
| May 5, 2026 | Gross margin % | FY2026 | 90% – 91% | New |
| May 5, 2026 | Weighted-average ordinary shares outstanding | FY2026 | 66 – 67 | New |
| May 5, 2026 | Weighted-average ordinary shares outstanding | FY2026 | 66 – 67 | New |
| May 5, 2026 | Effective tax rate | FY2026 | 0% – 10% | New |
| May 5, 2026 | Effective tax rate | FY2026 | 11.5% – 13.5% | New |
| May 5, 2026 | SG&A expenses | FY2026 | $1.42B – $1.50B | New |
| May 5, 2026 | R&D expenses | FY2026 | $811.00M – $867.00M | Lowered |
| May 5, 2026 | SG&A expenses | FY2026 | $1.26B – $1.32B | New |
| May 5, 2026 | R&D expenses | FY2026 | $725.00M – $775.00M | Lowered |
| May 5, 2026 | Total Revenues | FY2026 | $4.25B – $4.50B | New |
| Feb 24, 2026 | Gross margin % | FY2026 | 89% – 90% | New |
| Feb 24, 2026 | Gross margin % | FY2026 | 90% – 91% | New |
| Feb 24, 2026 | Weighted-average ordinary shares outstanding | FY2026 | 65 – 66 | New |
| Feb 24, 2026 | Weighted-average ordinary shares outstanding | FY2026 | 65 – 66 | New |
| Feb 24, 2026 | Effective tax rate | FY2026 | 0% – 10% | New |
| Feb 24, 2026 | Effective tax rate | FY2026 | 11.5% – 13.5% | New |
| Feb 24, 2026 | SG&A expenses | FY2026 | $1.42B – $1.50B | New |
| Feb 24, 2026 | R&D expenses | FY2026 | $811.00M – $867.00M | Lowered |
| Feb 24, 2026 | SG&A expenses | FY2026 | $1.26B – $1.32B | New |
| Feb 24, 2026 | R&D expenses | FY2026 | $725.00M – $775.00M | Lowered |
| Feb 24, 2026 | Total Revenues | FY2026 | $4.25B – $4.50B | New |
| Nov 5, 2025 | Net income per diluted share | FY2025 | $7.65 – $8.45 | Raised |
| Nov 5, 2025 | Net loss per diluted share | FY2025 | -$7.10 – -$5.20 | Raised |
| Nov 5, 2025 | Gross margin % | FY2025 | 88% | Reaffirmed |
| Nov 5, 2025 | Gross margin % | FY2025 | 92% | Reaffirmed |
| Nov 5, 2025 | Effective tax rate | FY2025 | 35% – 45% | Raised |
| Nov 5, 2025 | Effective tax rate | FY2025 | -20% – -15% | Lowered |
| Nov 5, 2025 | SG&A expenses | FY2025 | $1.79B – $1.85B | Raised |
| Nov 5, 2025 | R&D expenses | FY2025 | $771.00M – $810.00M | Lowered |
| Nov 5, 2025 | Acquired IPR&D | FY2025 | $948.00M | Raised |
| Nov 5, 2025 | Net loss | FY2025 | -$435.00M – -$315.00M | Lowered |
| Nov 5, 2025 | SG&A expenses | FY2025 | $1.59B – $1.63B | Raised |
| Nov 5, 2025 | R&D expenses | FY2025 | $680.00M – $710.00M | Lowered |
| Nov 5, 2025 | Acquired IPR&D | FY2025 | $948.00M | Raised |
| Nov 5, 2025 | Net income | FY2025 | $475.00M – $525.00M | Lowered |
| Nov 5, 2025 | Total Revenues | FY2025 | $4.18B – $4.28B | Narrowed |
| Aug 5, 2025 | Net income per diluted share | FY2025 | $4.80 – $5.60 | New |
| Aug 5, 2025 | Net loss per diluted share | FY2025 | -$9.25 – -$7.50 | New |
| Aug 5, 2025 | Gross margin % | FY2025 | 88% | New |
| Aug 5, 2025 | Gross margin % | FY2025 | 92% | New |
| Aug 5, 2025 | Weighted-average ordinary shares used in per share calculations | FY2025 | 61 – 62 | New |
| Aug 5, 2025 | Weighted-average ordinary shares used in per share calculations | FY2025 | 62 – 63 | New |
| Aug 5, 2025 | Effective tax rate | FY2025 | 4% – 16% | New |
| Aug 5, 2025 | Effective tax rate | FY2025 | 27% – 37% | New |
| Aug 5, 2025 | SG&A expenses | FY2025 | $1.62B – $1.69B | New |
| Aug 5, 2025 | R&D expenses | FY2025 | $805.00M – $865.00M | Lowered |
| Aug 5, 2025 | Acquired IPR&D | FY2025 | $905.00M | Raised |
| Aug 5, 2025 | Net loss | FY2025 | -$565.00M – -$450.00M | Lowered |
| Aug 5, 2025 | SG&A expenses | FY2025 | $1.45B – $1.50B | New |
| Aug 5, 2025 | R&D expenses | FY2025 | $730.00M – $780.00M | Lowered |
| Aug 5, 2025 | Acquired IPR&D | FY2025 | $905.00M | Raised |
| Aug 5, 2025 | Net income | FY2025 | $300.00M – $350.00M | Lowered |
| Aug 5, 2025 | Total Revenues | FY2025 | $4.15B – $4.30B | New |
| May 6, 2025 | Net income per diluted share | FY2025 | $4.00 – $5.60 | Lowered |
| May 6, 2025 | Net income (loss) per diluted share | FY2025 | -$10.00 – -$7.50 | Lowered |
| May 6, 2025 | Gross margin % | FY2025 | 88% | Reaffirmed |
| May 6, 2025 | Gross margin % | FY2025 | 92% | Reaffirmed |
| May 6, 2025 | Effective tax rate | FY2025 | 0% – 10% | Raised |
| May 6, 2025 | Effective tax rate | FY2025 | 35% – 45% | Raised |
| May 6, 2025 | SG&A expenses | FY2025 | $1.64B – $1.72B | Raised |
| May 6, 2025 | R&D expenses | FY2025 | $835.00M – $895.00M | Lowered |
| May 6, 2025 | Acquired in-process research and development | FY2025 | $870.00M – $900.00M | Raised |
| May 6, 2025 | Net income (loss) | FY2025 | -$615.00M – -$450.00M | Lowered |
| May 6, 2025 | SG&A expenses | FY2025 | $1.47B – $1.53B | Raised |
| May 6, 2025 | R&D expenses | FY2025 | $760.00M – $810.00M | Lowered |
| May 6, 2025 | Acquired in-process research and development | FY2025 | $870.00M – $900.00M | Raised |
| May 6, 2025 | Net income | FY2025 | $250.00M – $350.00M | Lowered |
| May 6, 2025 | Total Revenues | FY2025 | $4.15B – $4.40B | Reaffirmed |
| Feb 25, 2025 | Net income per diluted share | FY2025 | $22.50 – $24.00 | New |
| Feb 25, 2025 | Net income per diluted share | FY2025 | $9.15 – $11.50 | New |
| Feb 25, 2025 | Gross margin % | FY2025 | 88% | New |
| Feb 25, 2025 | Gross margin % | FY2025 | 92% | New |
| Feb 25, 2025 | Weighted-average ordinary shares used in per share calculations | FY2025 | 62 – 63 | New |
| Feb 25, 2025 | Effective tax rate | FY2025 | -5% – 10% | New |
| Feb 25, 2025 | Effective tax rate | FY2025 | 13% – 15% | New |
| Feb 25, 2025 | SG&A expenses | FY2025 | $1.40B – $1.48B | New |
| Feb 25, 2025 | R&D expenses | FY2025 | $792.00M – $851.00M | Lowered |
| Feb 25, 2025 | Net income | FY2025 | $560.00M – $720.00M | Lowered |
| Feb 25, 2025 | SG&A expenses | FY2025 | $1.25B – $1.31B | New |
| Feb 25, 2025 | R&D expenses | FY2025 | $720.00M – $770.00M | Lowered |
| Feb 25, 2025 | Net income | FY2025 | $1.40B – $1.50B | Raised |
| Feb 25, 2025 | Total Revenues | FY2025 | $4.15B – $4.40B | Lowered |
| Nov 6, 2024 | Net income per diluted share | FY2024 | $19.50 – $20.60 | Raised |
| Nov 6, 2024 | Net income per diluted share | FY2024 | $6.70 – $8.50 | Raised |
| Nov 6, 2024 | Gross margin % | FY2024 | 89% | Reaffirmed |
| Nov 6, 2024 | Gross margin % | FY2024 | 93% | Reaffirmed |
| Nov 6, 2024 | SG&A expenses as % of total revenues | FY2024 | 33% – 35% | Raised |
| Nov 6, 2024 | R&D expenses as % of total revenues | FY2024 | 21% – 23% | Lowered |
| Nov 6, 2024 | Effective tax rate | FY2024 | -17% – -2% | Lowered |
| Nov 6, 2024 | SG&A expenses as % of total revenues | FY2024 | 29% – 31% | Raised |
| Nov 6, 2024 | R&D expenses as % of total revenues | FY2024 | 19% – 21% | Lowered |
| Nov 6, 2024 | Effective tax rate | FY2024 | 10% – 12% | Lowered |
| Nov 6, 2024 | Neuroscience (includes royalties from high-sodium oxybate AG) | FY2024 | $2.83B – $2.93B | Raised |
| Nov 6, 2024 | Oncology | FY2024 | $1.08B – $1.13B | Lowered |
| Nov 6, 2024 | SG&A expenses | FY2024 | $1.34B – $1.39B | Raised |
| Nov 6, 2024 | R&D expenses | FY2024 | $862.00M – $908.00M | Lowered |
| Nov 6, 2024 | Net income | FY2024 | $430.00M – $550.00M | Lowered |
| Nov 6, 2024 | SG&A expenses | FY2024 | $1.19B – $1.23B | Lowered |
| Nov 6, 2024 | R&D expenses | FY2024 | $790.00M – $830.00M | Lowered |
| Nov 6, 2024 | Net income | FY2024 | $1.28B – $1.35B | Raised |
| Nov 6, 2024 | Revenues | FY2024 | $4.00B – $4.10B | Reaffirmed |
| Jul 31, 2024 | Net income per diluted share 5 | FY2024 | $19.20 – $20.30 | Raised |
| Jul 31, 2024 | Net income per diluted share 5 | FY2024 | $6.00 – $8.00 | Raised |
| Jul 31, 2024 | Gross margin % | FY2024 | 89% | Reaffirmed |
| Jul 31, 2024 | Gross margin % | FY2024 | 93% | Reaffirmed |
| Jul 31, 2024 | Weighted-average ordinary shares used in per share calculations | FY2024 | 67 | New |
| Jul 31, 2024 | Weighted-average ordinary shares used in per share calculations | FY2024 | 67 | New |
| Jul 31, 2024 | SG&A expenses as % of total revenues | FY2024 | 33% – 36% | New |
| Jul 31, 2024 | R&D expenses as % of total revenues | FY2024 | 22% – 23% | Lowered |
| Jul 31, 2024 | Effective tax rate | FY2024 | -22% – -3% | Lowered |
| Jul 31, 2024 | SG&A expenses as % of total revenues | FY2024 | 29% – 31% | New |
| Jul 31, 2024 | R&D expenses as % of total revenues | FY2024 | 20% – 21% | Lowered |
| Jul 31, 2024 | Effective tax rate | FY2024 | 10% – 12% | Lowered |
| Jul 31, 2024 | –Neuroscience (includes royalties from high-sodium oxybate AG) | FY2024 | $2.83B – $2.93B | New |
| Jul 31, 2024 | –Oncology | FY2024 | $1.10B – $1.15B | Lowered |
| Jul 31, 2024 | SG&A expenses | FY2024 | $1.37B – $1.43B | New |
| Jul 31, 2024 | R&D expenses | FY2024 | $887.00M – $935.00M | Lowered |
| Jul 31, 2024 | Net income | FY2024 | $385.00M – $530.00M | Lowered |
| Jul 31, 2024 | SG&A expenses | FY2024 | $1.19B – $1.23B | New |
| Jul 31, 2024 | R&D expenses | FY2024 | $810.00M – $850.00M | Lowered |
| Jul 31, 2024 | Net income | FY2024 | $1.28B – $1.35B | Raised |
| Jul 31, 2024 | Revenues | FY2024 | $4.00B – $4.10B | Lowered |
| May 1, 2024 | Net income per diluted share | FY2024 | $18.15 – $19.35 | Reaffirmed |
| May 1, 2024 | Net income per diluted share | FY2024 | $5.80 – $7.70 | Reaffirmed |
| May 1, 2024 | Gross margin % | FY2024 | 89% | Reaffirmed |
| May 1, 2024 | Gross margin % | FY2024 | 93% | Reaffirmed |
| May 1, 2024 | Revenues | FY2024 | $4.00B – $4.20B | Reaffirmed |
| Feb 28, 2024 | Net income per diluted share | FY2024 | $18.15 – $19.35 | New |
| Feb 28, 2024 | Net income per diluted share | FY2024 | $5.80 – $7.70 | New |
| Feb 28, 2024 | Gross margin % | FY2024 | 89% | New |
| Feb 28, 2024 | Gross margin % | FY2024 | 93% | New |
| Feb 28, 2024 | Revenues | FY2024 | $4.00B – $4.20B | New |
| Nov 8, 2023 | Net income per diluted share | FY2023 | $18.15 – $19.00 | Reaffirmed |
| Nov 8, 2023 | Net income per diluted share | FY2023 | $6.60 – $8.15 | Reaffirmed |
| Nov 8, 2023 | Gross margin % | FY2023 | 89% | Reaffirmed |
| Nov 8, 2023 | Gross margin % | FY2023 | 93% | Reaffirmed |
| Nov 8, 2023 | Revenues | FY2023 | $3.75B – $3.88B | Raised |
| Aug 9, 2023 | Net income per diluted share | FY2023 | $18.15 – $19.00 | Raised |
| Aug 9, 2023 | Net income per diluted share | FY2023 | $6.60 – $8.15 | Raised |
| Aug 9, 2023 | Gross margin % | FY2023 | 89% | Reaffirmed |
| Aug 9, 2023 | Gross margin % | FY2023 | 93% | Reaffirmed |
| Aug 9, 2023 | R&D expenses as % of total revenues | FY2023 | 19% – 21% | Lowered |
| Aug 9, 2023 | Effective tax rate | FY2023 | -35% – -15% | Lowered |
| Aug 9, 2023 | SG&A expenses as % of total revenues | FY2023 | 27% – 30% | Raised |
| Aug 9, 2023 | R&D expenses as % of total revenues | FY2023 | 17% – 19% | Lowered |
| Aug 9, 2023 | Effective tax rate | FY2023 | 8% – 10% | Lowered |
| Aug 9, 2023 | SG&A expenses | FY2023 | $1.22B – $1.30B | Raised |
| Aug 9, 2023 | R&D expenses | FY2023 | $739.00M – $793.00M | Lowered |
| Aug 9, 2023 | SG&A expenses | FY2023 | $1.05B – $1.11B | Lowered |
| Aug 9, 2023 | R&D expenses | FY2023 | $675.00M – $725.00M | Lowered |
| Aug 9, 2023 | Net income | FY2023 | $1.29B – $1.34B | Raised |
| Aug 9, 2023 | Net income | FY2023 | $450.00M – $565.00M | Lowered |
| Aug 9, 2023 | Weighted-average ordinary shares used in per share calculations | FY2023 | 72 | Lowered |
| Aug 9, 2023 | Weighted-average ordinary shares used in per share calculations | FY2023 | 72 | Lowered |
| Aug 9, 2023 | SG&A expenses as % of total revenues | FY2023 | 31% – 35% | Raised |
| Aug 9, 2023 | Revenues | FY2023 | $3.73B – $3.88B | Raised |
| Aug 9, 2023 | –Neuroscience (includes royalties from high-sodium oxybate AG) | FY2023 | $2.72B – $2.83B | Lowered |
| Aug 9, 2023 | –Oncology | FY2023 | $950.00M – $1.05B | Lowered |
| May 10, 2023 | Net income per diluted share | FY2023 | $16.90 – $17.85 | Reaffirmed |
| May 10, 2023 | Net income per diluted share | FY2023 | $5.90 – $7.90 | Reaffirmed |
| May 10, 2023 | Gross margin % | FY2023 | 89% | Reaffirmed |
| May 10, 2023 | Gross margin % | FY2023 | 93% | Reaffirmed |
| May 10, 2023 | Weighted-average ordinary shares used in per share calculations | FY2023 | 75 | New |
| May 10, 2023 | Weighted-average ordinary shares used in per share calculations | FY2023 | 75 | New |
| May 10, 2023 | SG&A expenses as % of total revenues | FY2023 | 31% – 35% | New |
| May 10, 2023 | R&D expenses as % of total revenues | FY2023 | 19% – 22% | Lowered |
| May 10, 2023 | Effective tax rate | FY2023 | -32% – -8% | Lowered |
| May 10, 2023 | SG&A expenses as % of total revenues | FY2023 | 27% – 30% | New |
| May 10, 2023 | R&D expenses as % of total revenues | FY2023 | 17% – 20% | Lowered |
| May 10, 2023 | Effective tax rate | FY2023 | 9% – 11% | Lowered |
| May 10, 2023 | –Neuroscience (includes royalties from high-sodium oxybate AG) | FY2023 | $2.68B – $2.83B | New |
| May 10, 2023 | –Oncology | FY2023 | $950.00M – $1.05B | Lowered |
| May 10, 2023 | SG&A expenses | FY2023 | $1.20B – $1.28B | New |
| May 10, 2023 | R&D expenses | FY2023 | $739.00M – $797.00M | Lowered |
| May 10, 2023 | Net income | FY2023 | $410.00M – $560.00M | Lowered |
| May 10, 2023 | SG&A expenses | FY2023 | $1.05B – $1.11B | New |
| May 10, 2023 | R&D expenses | FY2023 | $675.00M – $725.00M | Lowered |
| May 10, 2023 | Net income | FY2023 | $1.24B – $1.31B | Raised |
| May 10, 2023 | Revenues | FY2023 | $3.68B – $3.88B | Reaffirmed |
| Mar 1, 2023 | Net income per diluted share | FY2023 | $16.90 – $17.85 | New |
| Mar 1, 2023 | Net income per diluted share | FY2023 | $5.90 – $7.90 | New |
| Mar 1, 2023 | Gross margin % | FY2023 | 89% | New |
| Mar 1, 2023 | Gross margin % | FY2023 | 93% | New |
| Mar 1, 2023 | total revenue guidance | FY2023 | $3.68B – $3.88B | New |
| Nov 9, 2022 | Net income per diluted share | FY2022 | $17.20 – $17.85 | Raised |
| Nov 9, 2022 | Net income per diluted share | FY2022 | $0.75 – $2.75 | Lowered |
| Nov 9, 2022 | Gross margin % | FY2022 | 85% | Reaffirmed |
| Nov 9, 2022 | Gross margin % | FY2022 | 93% | Reaffirmed |
| Nov 9, 2022 | Revenues | FY2022 | $3.60B – $3.70B | Raised |
| Aug 3, 2022 | Net income per diluted share | FY2022 | $16.70 – $17.70 | Reaffirmed |
| Aug 3, 2022 | Net income per diluted share | FY2022 | $1.45 – $3.95 | Raised |
| Aug 3, 2022 | Gross margin % | FY2022 | 85% | Raised |
| Aug 3, 2022 | Gross margin % | FY2022 | 93% | Reaffirmed |
| Aug 3, 2022 | Weighted-average ordinary shares used in per share calculations | FY2022 | 63 – 72 | Reaffirmed |
| Aug 3, 2022 | Weighted-average ordinary shares used in per share calculations | FY2022 | 72 | Reaffirmed |
| Aug 3, 2022 | SG&A expenses as % of total revenues | FY2022 | 35% – 40% | Raised |
| Aug 3, 2022 | R&D expenses as % of total revenues | FY2022 | 17% – 19% | Lowered |
| Aug 3, 2022 | Effective tax rate | FY2022 | -22% – 1104% | Raised |
| Aug 3, 2022 | SG&A expenses as % of total revenues | FY2022 | 29% – 32% | Raised |
| Aug 3, 2022 | R&D expenses as % of total revenues | FY2022 | 15% – 17% | Lowered |
| Aug 3, 2022 | Effective tax rate | FY2022 | 10% – 12% | Lowered |
| Aug 3, 2022 | Neuroscience | FY2022 | $2.60B – $2.80B | Raised |
| Aug 3, 2022 | Oncology | FY2022 | $840.00M – $920.00M | Lowered |
| Aug 3, 2022 | SG&A expenses | FY2022 | $1.30B – $1.39B | Raised |
| Aug 3, 2022 | R&D expenses | FY2022 | $621.00M – $669.00M | Lowered |
| Aug 3, 2022 | Acquired in-process research and development expenses | FY2022 | $69.00M | Lowered |
| Aug 3, 2022 | Net income | FY2022 | $90.00M – $255.00M | Raised |
| Aug 3, 2022 | SG&A expenses | FY2022 | $1.08B – $1.13B | Lowered |
| Aug 3, 2022 | R&D expenses | FY2022 | $560.00M – $600.00M | Lowered |
| Aug 3, 2022 | Acquired in-process research and development expenses | FY2022 | $69.00M | Lowered |
| Aug 3, 2022 | Net income | FY2022 | $1.18B – $1.25B | Raised |
| Aug 3, 2022 | total revenue guidance | FY2022 | $3.50B – $3.70B | Reaffirmed |
| May 4, 2022 | Net income per diluted share | FY2022 | $16.70 – $17.70 | Raised |
| May 4, 2022 | Net income per diluted share | FY2022 | $0.25 – $3.20 | Lowered |
| May 4, 2022 | Gross margin % | FY2022 | 84% | Raised |
| May 4, 2022 | Gross margin % | FY2022 | 93% | Raised |
| May 4, 2022 | R&D expenses as % of total revenues | FY2022 | 17% – 19% | Lowered |
| May 4, 2022 | Effective tax rate | FY2022 | -117% – -30% | Lowered |
| May 4, 2022 | SG&A expenses as % of total revenues | FY2022 | 29% – 32% | Raised |
| May 4, 2022 | R&D expenses as % of total revenues | FY2022 | 15% – 17% | Lowered |
| May 4, 2022 | Effective tax rate | FY2022 | 10% – 12% | Lowered |
| May 4, 2022 | –Neuroscience (includes potential Xyrem authorized generic royalties) | FY2022 | $2.60B – $2.80B | New |
| May 4, 2022 | SG&A expenses | FY2022 | $1.30B – $1.39B | Raised |
| May 4, 2022 | R&D expenses | FY2022 | $621.00M – $669.00M | Lowered |
| May 4, 2022 | Acquired in-process research and development expenses | FY2022 | $65.00M | Lowered |
| May 4, 2022 | Net income | FY2022 | $15.00M – $200.00M | Raised |
| May 4, 2022 | SG&A expenses | FY2022 | $1.08B – $1.13B | Lowered |
| May 4, 2022 | R&D expenses | FY2022 | $560.00M – $600.00M | Lowered |
| May 4, 2022 | Acquired in-process research and development expenses | FY2022 | $65.00M | Lowered |
| May 4, 2022 | –Oncology | FY2022 | $840.00M – $920.00M | Lowered |
| May 4, 2022 | Net income | FY2022 | $1.18B – $1.25B | Raised |
| May 4, 2022 | Weighted-average ordinary shares used in per share calculations | FY2022 | 63 – 72 | Lowered |
| May 4, 2022 | Weighted-average ordinary shares used in per share calculations | FY2022 | 72 | Reaffirmed |
| May 4, 2022 | SG&A expenses as % of total revenues | FY2022 | 35% – 40% | Raised |
| May 4, 2022 | Revenues | FY2022 | $3.50B – $3.70B | Raised |
| Mar 1, 2022 | Net income per diluted share | FY2022 | $16.00 – $17.00 | New |
| Mar 1, 2022 | Net income per diluted share | FY2022 | $0.50 – $3.00 | New |
| Mar 1, 2022 | Gross margin % | FY2022 | 83% | New |
| Mar 1, 2022 | Gross margin % | FY2022 | 92% | New |
| Mar 1, 2022 | Weighted-average ordinary shares used in per share calculations | FY2022 | 72 | New |
| Mar 1, 2022 | Weighted-average ordinary shares used in per share calculations | FY2022 | 72 | New |
| Mar 1, 2022 | SG&A expenses as % of total revenues | FY2022 | 35% – 40% | New |
| Mar 1, 2022 | R&D expenses as % of total revenues | FY2022 | 17% – 19% | Lowered |
| Mar 1, 2022 | Effective tax rate | FY2022 | -116% – -32% | Lowered |
| Mar 1, 2022 | SG&A expenses as % of total revenues | FY2022 | 31% – 34% | New |
| Mar 1, 2022 | R&D expenses as % of total revenues | FY2022 | 15% – 17% | Lowered |
| Mar 1, 2022 | Effective tax rate | FY2022 | 10% – 12% | Lowered |
| Mar 1, 2022 | SG&A expenses | FY2022 | $1.30B – $1.40B | New |
| Mar 1, 2022 | R&D expenses | FY2022 | $621.00M – $670.00M | Lowered |
| Mar 1, 2022 | Net income | FY2022 | $10.00M – $185.00M | Lowered |
| Mar 1, 2022 | SG&A expenses | FY2022 | $1.12B – $1.19B | New |
| Mar 1, 2022 | R&D expenses | FY2022 | $560.00M – $600.00M | Lowered |
| Mar 1, 2022 | Net income | FY2022 | $1.13B – $1.20B | Raised |
| Mar 1, 2022 | Revenues | FY2022 | $3.46B – $3.66B | New |
| Mar 1, 2022 | –Neuroscience (includes potential Xyrem authorized generic royalties) | FY2022 | $2.56B – $2.76B | Lowered |
| Mar 1, 2022 | –Oncology | FY2022 | $840.00M – $920.00M | Lowered |
| Jan 10, 2022 | revenue guidance | FY2021 | $3.02B – $3.10B | Reaffirmed |
| Jan 10, 2022 | revenue | FY2025 | $5.00B | New |
| Nov 9, 2021 | Net income per diluted share | FY2021 | $15.10 – $15.80 | New |
| Nov 9, 2021 | Net loss per diluted share | FY2021 | -$7.00 – -$5.40 | New |
| Nov 9, 2021 | Gross margin % | FY2021 | 93% | New |
| Nov 9, 2021 | Gross margin % | FY2021 | 85% | New |
| Nov 9, 2021 | SG&A expenses as % of total revenues | FY2021 | 34% – 36% | New |
| Nov 9, 2021 | R&D expenses as % of total revenues | FY2021 | 15% – 16% | Lowered |
| Nov 9, 2021 | -Neuroscience | FY2021 | $2.28B – $2.35B | New |
| Nov 9, 2021 | -Oncology | FY2021 | $715.00M – $735.00M | Lowered |
| Nov 9, 2021 | SG&A expenses | FY2021 | $1.40B – $1.45B | New |
| Nov 9, 2021 | R&D expenses | FY2021 | $514.00M – $548.00M | Lowered |
| Nov 9, 2021 | Net loss | FY2021 | -$420.00M – -$320.00M | Lowered |
| Nov 9, 2021 | SG&A expenses | FY2021 | $1.06B – $1.10B | New |
| Nov 9, 2021 | R&D expenses | FY2021 | $465.00M – $485.00M | Lowered |
| Nov 9, 2021 | Adjusted net income | FY2021 | $925.00M – $965.00M | Raised |
| Nov 9, 2021 | Effective tax rate | FY2021 | 11% – 13% | Lowered |
| Nov 9, 2021 | Weighted-average ordinary shares used in per share calculations | FY2021 | 60 | New |
| Nov 9, 2021 | Weighted-average ordinary shares used in per share calculations | FY2021 | 61 | New |
| Nov 9, 2021 | SG&A expenses as % of total revenues | FY2021 | 45% – 48% | New |
| Nov 9, 2021 | R&D expenses as % of total revenues | FY2021 | 17% – 18% | Lowered |
| Nov 9, 2021 | Effective tax rate | FY2021 | -183% – -110% | Lowered |
| Nov 9, 2021 | Revenues | FY2021 | $3.02B – $3.10B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Jazz Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- News
- News
- Update
- Results
- Results
- Results
- Results
- News
- Results
- Results
- Update
- Results
- Update